Compare MAT & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAT | KRYS |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | MAT | KRYS |
|---|---|---|
| Price | $20.72 | $284.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $24.75 | ★ $250.50 |
| AVG Volume (30 Days) | ★ 2.7M | 291.8K |
| Earning Date | 02-10-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | 1.32 | ★ 6.66 |
| Revenue | ★ $5,227,568,000.00 | $373,164,000.00 |
| Revenue This Year | $1.92 | $36.14 |
| Revenue Next Year | $3.47 | $42.38 |
| P/E Ratio | ★ $15.77 | $43.40 |
| Revenue Growth | N/A | ★ 54.51 |
| 52 Week Low | $13.95 | $122.80 |
| 52 Week High | $22.26 | $295.98 |
| Indicator | MAT | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 65.40 |
| Support Level | $20.41 | $271.52 |
| Resistance Level | $21.35 | $295.98 |
| Average True Range (ATR) | 0.67 | 12.40 |
| MACD | -0.09 | 0.91 |
| Stochastic Oscillator | 32.83 | 79.43 |
Mattel manufactures and markets toy products that are sold to its wholesale and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2024, with the remainder stemming from international markets.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.